查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1555655

胚胎著床前遺傳學的檢驗(PGT)市場:全球產業分析，規模，佔有率，成長，趨勢，預測，2024-2031年

Preimplantation Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 177 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research最近發布了一份有關全球植入前基因檢測 (PGT) 市場的詳細報告。該報告對市場推動因素、趨勢、機會和課題等關鍵市場動態進行了全面分析，提供了對市場結構的深入見解。

主要的洞察

  • 植入前基因檢測 (PGT) 市場規模（2024 年）：6.8 億美元
  • 預估市場規模（2031 年）：14.8 億美元
  • 全球市場成長率（2024 年至 2031 年複合年增長率）：9%

植入前基因檢測 (PGT) 市場 - 報告範圍：

植入前基因檢測（PGT）市場涵蓋了不孕症治療中使用的各種基因檢測程序，特別是在體外受精（IVF）過程中。植入前基因檢測（PGT）可以篩檢胚胎是否有遺傳疾病，並增加健康懷孕的機會。由於人們對遺傳疾病認識的提高、不孕症治療的進步以及精準健康和個人化醫療的結合，該市場正在不斷擴大。 PGT 可應用於多種場合，包括醫院、生育診所和家庭使用。不孕率上升、延遲出生和基因檢測技術進步推動了成長。

推動市場成長的因素：

基因技術的進展

次世代定序 (NGS) 和 CRISPR 等基因技術的快速進步是 PGT 市場的關鍵推動因素。這些技術可以實現更準確、高效和全面的基因篩檢，提高胚胎基因異常檢測的準確性。 NGS 允許同時分析多個基因，從而減少與基因檢測相關的時間和成本。非侵入性檢測的發展使準父母更容易接受和接受PGT，從而推動了對更健康懷孕和預防遺傳疾病的需求。

不孕​​率上升和生育延遲

不孕​​率上升和分娩延遲的全球趨勢對市場成長做出了重大貢獻。壓力、飲食和環境污染物等生活方式因素與不孕率增加有關。隨著越來越多的夫婦選擇晚育，染色體異常的風險增加，使得PGT成為選擇健康胚胎和降低遺傳風險的重要工具。隨著夫妻尋求確保懷孕的健康和生存能力，人們對輔助生殖技術 (ART) 的認識不斷提高，進一步推動了對 PGT 的需求。

接受度與認知度提升

減少不孕症治療帶來的恥辱以及提高對基因檢測益處的認識正在推動市場擴張。教育活動、遺傳諮詢的進步和媒體報告提高了公眾意識並促使 PGT 的廣泛接受。隨著夫妻越來越了解基因篩檢的好處，對 PGT 的需求正在增加。保險公司也認識到 PGT 保險的好處，進一步推動市場成長。

市場阻礙因素：

成本高且可訪問性有限

PGT 的高成本是市場的主要限制。基因檢測所需的複雜技術使得該程序昂貴並限制了其可近性，特別是在醫療基礎設施有限的發展中國家。此外，PGT 不受保險保障，這限制了高收入者的使用。這種經濟障礙限制了那些能夠支付自付費用的人的進入，從而阻礙了市場的成長潛力。

道德與法律問題

基於遺傳特徵選擇胚胎的倫理擔憂引發了有關優生學和遺傳歧視的複雜問題。這些擔憂導致社會動盪和監管課題，影響市場成長。不同地區的監管環境差異很大，一些國家對基因檢測實施嚴格監管或禁止，使市場擴張更加複雜。

市場機會：

個人化醫療與精準健康的融合

個人化醫療的整合為PGT市場帶來了重大機會。隨著醫療保健越來越多地採用個人化方法，PGT 透過選擇基因健康的胚胎無縫地適應了這一趨勢。基因組學和人工智慧的進步使 PGT 更加準確和易於使用，滿足了對客製化醫療解決方案不斷增長的需求。預測遺傳風險和客製化治療計劃的能力與現代醫療保健對精確度的強調相一致，為 PGT 市場創造了巨大的成長機會。

本報告涵蓋的主要問題

  • 推動全球胚胎植入前基因檢測 (PGT) 市場發展的關鍵因素有哪些？
  • 推動植入前基因檢測 (PGT) 市場的程序和應用有哪些？
  • 科技進步如何形塑競爭格局？
  • 市場上的主要參與者有哪些？
  • 全球PGT市場的新趨勢和未來前景是什麼？

目錄

第1章 摘要整理

第2章 市場概要

  • 市場範圍和定義
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
    • 主要趨勢
  • 宏觀經濟要素
    • 全球各部門展望
    • 全球GDP成長預測
    • 全球醫療保健支出預測
  • COVID-19影響分析
  • 預測要素- 相關性及影響

第3章 附加價值的洞察

  • 流行病學-疾病的得病率和發生率
  • 技術評估
  • 法規情形
  • 價值鏈分析
  • 主要的交易與合併
  • 大環境分析
  • 波特的五力分析

第4章 全球胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

  • 主要的焦點
    • 市場規模(金額)和與前一年同期比較成長率
    • 絕對的商機
  • 市場規模(金額)的分析與預測
    • 過去的市場規模(金額)分析，2019年～2023年
    • 目前市場規模(金額)分析與預測，2023～2031年
  • 全球胚胎著床前遺傳學的檢驗(PGT)市場展望:檢驗類型
    • 簡介/主要調查結果
    • 過去的市場規模(金額)分析，檢驗各類型，2019～2023年
    • 目前市場規模(金額)分析與預測，檢驗各類型，2024～2031年
      • 診斷
      • 篩檢
  • 市場魅力分析:檢驗類型
  • 全球胚胎著床前遺傳學的檢驗(PGT)市場展望:技術
    • 簡介/主要調查結果
    • 過去的市場規模(金額)分析，各技術，2019～2023年
    • 目前市場規模(金額)分析與預測，各技術，2024～2031年
      • CGH為基礎的
      • FISH為基礎的
      • NGS為基礎的
      • SNP為基礎的
      • PCR為基礎的
  • 市場魅力分析:技術
  • 全球胚胎著床前遺傳學的檢驗(PGT)市場展望:終端用戶
    • 簡介/主要調查結果
    • 過去的市場規模(金額)分析，各終端用戶，2019～2023年
    • 目前市場規模(金額)分析與預測，各終端用戶，2024～2031年
      • 感染疾病
      • 神經疾病
      • 自體免疫疾病
      • 腫瘤學
      • 其他
  • 市場魅力分析:終端用戶

第5章 全球胚胎著床前遺傳學的檢驗(PGT)市場展望:地區

  • 主要的焦點
  • 過去的市場規模(金額)分析，各地區，2019～2023年
  • 目前市場規模(金額)分析與預測，各地區，2024～2031年
    • 北美
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 南美
    • 中東·非洲
  • 市場魅力分析:地區

第6章 北美的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第7章 歐洲的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第8章 東亞的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第9章 南亞及大洋洲的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第10章 南美的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第11章 中東及非洲的胚胎著床前遺傳學的檢驗(PGT)市場展望:過去(2019年～2023年)及預測(2024年～2031年)

第12章 競爭情形

  • 市場佔有率分析，2023年
  • 市場結構
    • 各市場的競爭激烈化地圖
    • 競爭儀表板
  • 企業簡介(詳細內容- 概要，財務，策略，最近的趨勢)
    • Agilent Technologies Inc.
    • Abbott Laboratories
    • CooperSurgical Inc.
    • Oxford Gene Technology IP
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • PerkinElmer Inc.
    • Genea Limited
    • Natera Inc.
    • Rubicon Genomics Inc.
    • CombiMatrix Corporation

第13章 附錄

  • 調查手法
  • 調查的前提條件
  • 縮寫和簡稱
簡介目錄
Product Code: PMRREP34757

Persistence Market Research has recently published an extensive report on the global Preimplantation Genetic Testing (PGT) Market. This report offers a comprehensive analysis of key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Preimplantation Genetic Testing Market Size (2024E): USD 0.68 Bn
  • Projected Market Value (2031F): USD 1.48 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 9%

Preimplantation Genetic Testing Market - Report Scope:

The Preimplantation Genetic Testing (PGT) Market covers a range of genetic testing procedures used in fertility treatments, particularly in in-vitro fertilization (IVF) processes. PGT allows for the screening of embryos for genetic disorders, increasing the chances of healthy pregnancies. The market is expanding due to the rising awareness of genetic disorders, advancements in fertility treatments, and the integration of precision health and personalized medicine. PGT finds applications in various settings, including hospitals, fertility clinics, and home use. The growth is driven by increasing infertility rates, delayed childbearing, and technological advancements in genetic testing.

Market Growth Drivers:

Advances in Genetic Technology

Rapid advancements in genetic technology, such as next-generation sequencing (NGS) and CRISPR, are key drivers of the PGT market. These technologies allow for more accurate, efficient, and comprehensive genetic screening, improving the precision of detecting genetic anomalies in embryos. NGS enables the analysis of multiple genes simultaneously, reducing both time and costs associated with genetic testing. The development of non-invasive testing methods is making PGT more accessible and acceptable to prospective parents, driving demand for healthier pregnancies and the prevention of genetic disorders.

Rising Infertility Rates and Delayed Childbearing

Increasing infertility rates and a global trend towards delayed childbearing are contributing significantly to the market's growth. Lifestyle factors, including stress, diet, and environmental pollutants, are leading to higher infertility rates. As more couples opt to have children later in life, the risk of chromosomal abnormalities increases, making PGT a critical tool for selecting healthy embryos and reducing genetic risks. The growing awareness of assisted reproductive technologies (ART) is further boosting demand for PGT, as couples seek to ensure the health and viability of their pregnancies.

Growing Acceptance and Awareness

Increasing awareness of the benefits of genetic testing, along with the decreasing stigma surrounding fertility treatments, is driving market expansion. Educational campaigns, advancements in genetic counseling, and media coverage are raising public awareness, leading to a broader acceptance of PGT. As couples become more informed about the benefits of genetic screening, demand for PGT rises. Insurance companies are also recognizing the benefits of covering PGT, further driving market growth.

Market Restraints:

High Costs and Limited Accessibility

The high costs associated with PGT are a significant restraint on the market. The advanced technologies required for genetic testing make the procedure expensive, limiting its accessibility, particularly in developing countries with limited healthcare infrastructure. The lack of insurance coverage for PGT also limits its accessibility to higher-income individuals. This financial barrier hampers the market's growth potential by restricting access to those who can afford the out-of-pocket expenses.

Ethical and Legal Concerns

Ethical concerns regarding the selection of embryos based on genetic characteristics raise complex questions about eugenics and genetic discrimination. These concerns lead to public apprehension and regulatory challenges, which impact the market's growth. Regulatory environments vary significantly across regions, with some countries imposing strict regulations or bans on genetic testing, further complicating market expansion.

Market Opportunities:

Integration of Personalized Medicine and Precision Health

The integration of personalized medicine presents a significant opportunity for the PGT market. As healthcare increasingly adopts personalized approaches, PGT fits seamlessly into this trend by enabling the selection of genetically healthy embryos. With advancements in genomics and artificial intelligence, PGT is becoming more accurate and accessible, meeting the growing demand for tailored healthcare solutions. The ability to predict genetic risks and customize treatment plans aligns with modern healthcare's focus on precision, creating substantial growth opportunities in the PGT market.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Preimplantation Genetic Testing (PGT) Market?
  • Which procedures and applications are leading in the PGT market?
  • How are technological advancements shaping the competitive landscape?
  • Who are the key players in the market, and what strategies are they employing?
  • What are the emerging trends and future prospects for the global PGT market?

Competitive Intelligence and Business Strategy:

Key players in the global Preimplantation Genetic Testing Market are focusing on research and development to innovate and enhance their product offerings. Companies are investing in advanced technologies like AI for genetic analysis, making PGT more efficient and accessible. Collaborations with fertility clinics and hospitals are strengthening their market presence. Emphasis on consumer education and marketing strategies fosters growth and brand loyalty in the evolving PGT market landscape.

Key Market Players

  • Quest Diagnostics Incorporated
  • Natera, Inc.
  • COOPER SURGICAL, INC.
  • Genea Pty Limited.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Bioarray S.L.
  • Illumina, Inc.
  • Igenomix
  • RGI
  • F. Hoffmann-La Roche Ltd.

Market Segmentation

By Procedure

  • Genetic Diagnosis
  • Genetic Screening

By Product

  • Reagents
  • Instruments

By Technology

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Preimplantation Genetic Testing Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Epidemiology - Disease Prevalence and Incidence
  • 3.2. Technology Assessment
  • 3.3. Regulatory Landscape
  • 3.4. Value Chain Analysis
  • 3.5. Key Deals and Mergers
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
  • 4.3. Global Preimplantation Genetic Testing Market Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
      • 4.3.3.1. Diagnostics
      • 4.3.3.2. Screening
  • 4.4. Market Attractiveness Analysis: Test Type
  • 4.5. Global Preimplantation Genetic Testing Market Outlook: Technology
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
      • 4.5.3.1. CGH-based
      • 4.5.3.2. FISH-based
      • 4.5.3.3. NGS-based
      • 4.5.3.4. SNP-based
      • 4.5.3.5. PCR-based
  • 4.6. Market Attractiveness Analysis: Technology
  • 4.7. Global Preimplantation Genetic Testing Market Outlook: End User
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
      • 4.7.3.1. Infectious Diseases
      • 4.7.3.2. Neurological Diseases
      • 4.7.3.3. Autoimmune Diseases
      • 4.7.3.4. Oncology
      • 4.7.3.5. Others
  • 4.8. Market Attractiveness Analysis: End User

5. Global Preimplantation Genetic Testing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Technology
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 6.4.1. Diagnostics
    • 6.4.2. Screening
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 6.5.1. CGH-based
    • 6.5.2. FISH-based
    • 6.5.3. NGS-based
    • 6.5.4. SNP-based
    • 6.5.5. PCR-based
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 6.6.1. Hospitals
    • 6.6.2. Diagnostic Labs
    • 6.6.3. Research & Academic Institutions
    • 6.6.4. Specialized Clinics
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Technology
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 7.4.1. Diagnostics
    • 7.4.2. Screening
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 7.5.1. CGH-based
    • 7.5.2. FISH-based
    • 7.5.3. NGS-based
    • 7.5.4. SNP-based
    • 7.5.5. PCR-based
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 7.6.1. Hospitals
    • 7.6.2. Diagnostic Labs
    • 7.6.3. Research & Academic Institutions
    • 7.6.4. Specialized Clinics
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Technology
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 8.4.1. Diagnostics
    • 8.4.2. Screening
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 8.5.1. CGH-based
    • 8.5.2. FISH-based
    • 8.5.3. NGS-based
    • 8.5.4. SNP-based
    • 8.5.5. PCR-based
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 8.6.1. Hospitals
    • 8.6.2. Diagnostic Labs
    • 8.6.3. Research & Academic Institutions
    • 8.6.4. Specialized Clinics
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Technology
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 9.4.1. Diagnostics
    • 9.4.2. Screening
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 9.5.1. CGH-based
    • 9.5.2. FISH-based
    • 9.5.3. NGS-based
    • 9.5.4. SNP-based
    • 9.5.5. PCR-based
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 9.6.1. Hospitals
    • 9.6.2. Diagnostic Labs
    • 9.6.3. Research & Academic Institutions
    • 9.6.4. Specialized Clinics
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Technology
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 10.4.1. Diagnostics
    • 10.4.2. Screening
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 10.5.1. CGH-based
    • 10.5.2. FISH-based
    • 10.5.3. NGS-based
    • 10.5.4. SNP-based
    • 10.5.5. PCR-based
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 10.6.1. Hospitals
    • 10.6.2. Diagnostic Labs
    • 10.6.3. Research & Academic Institutions
    • 10.6.4. Specialized Clinics
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Technology
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 11.4.1. Diagnostics
    • 11.4.2. Screening
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 11.5.1. CGH-based
    • 11.5.2. FISH-based
    • 11.5.3. NGS-based
    • 11.5.4. SNP-based
    • 11.5.5. PCR-based
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 11.6.1. Hospitals
    • 11.6.2. Diagnostic Labs
    • 11.6.3. Research & Academic Institutions
    • 11.6.4. Specialized Clinics
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Agilent Technologies Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Abbott Laboratories
    • 12.3.3. CooperSurgical Inc.
    • 12.3.4. Oxford Gene Technology IP
    • 12.3.5. Illumina Inc.
    • 12.3.6. Thermo Fisher Scientific Inc.
    • 12.3.7. PerkinElmer Inc.
    • 12.3.8. Genea Limited
    • 12.3.9. Natera Inc.
    • 12.3.10. Rubicon Genomics Inc.
    • 12.3.11. CombiMatrix Corporation

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations